Trial Condition(s):

Leiomyoma

Mode of action study of vilaprisan and ulipristal acetate in patients with uterine fibroids for whom surgery is planned

Bayer Identifier:

15791

ClinicalTrials.gov Identifier:

NCT03342859

EudraCT Number:

2017-000468-13

Terminated/Withdrawn

Trial Purpose

To investigate the clinical effects of vilaprisan and ulipristal acetate at molecular and cellular level on uterine and fibroid tissue taken from patients (after surgery / biopsy)

Inclusion Criteria
- Patients 18 years and older and premenopausal (based on gynecological history i.e. still menstruating; no significant estrogen deficiency symptoms)
- Diagnosis of uterine fibroids documented by ultrasound and relevant symptoms reported by the patient (e.g. heavy menstrual bleeding, pelvic pressure)
- Patients for whom surgery (hysterectomy or myomectomy) for the treatment of symptomatic uterine fibroids is planned
- Patients who are otherwise healthy as shown by medical history, physical and gynecological examinations, and laboratory test results
Exclusion Criteria
- Contraindications for the progesterone receptor modulators (PRM) vilaprisan or ulipristal acetate
- Use of medication that might interfere with the conduct of the study or the interpretation of the results (e.g. continuing use of hormonal contraceptives, tranexamic acid or other treatments for heavy menstrual bleeding, progesterone receptor modulators, gonadotropin-releasing hormone agonist, anticoagulants, moderate and strong CYP3A4 inducers and moderate and strong CYP3A4 inhibitors within a defined time period before treatment starts.

Trial Summary

Enrollment Goal
10
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Vilaprisan (BAY1002670)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Edinburgh Royal Infirmary/ NHS Lothian

Edinburgh, United Kingdom, EH16 4TJ

Status
Active, not recruiting
 

Trial Design